Supplementary Materials

Supplementary Material for:

Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma

Khun Visith Keu, Timothy H. Witney, Shahriar Yaghoubi, Jarrett Rosenberg, Anita Kurien, Rachel Magnusson, John Williams, Frezghi Habte, Jamie R. Wagner, Stephen Forman, Christine Brown, Martin Allen-Auerbach, Johannes Czernin, Winson Tang, Michael C. Jensen, Behnam Badie, Sanjiv S. Gambhir*

*Corresponding author. Email: sgambhir{at}stanford.edu

Published 18 January 2017, Sci. Transl. Med. 9, eaag2196 (2017)
DOI: 10.1126/scitranslmed.aag2196

This PDF file includes:

  • Fig. S1. [18F]FHBG uptake in parental and genetically modified CTLs.
  • Fig. S2. Assessment of FHBG toxicity to transduced CTLs.
  • Fig. S3. [18F]FHBG whole body biodistribution.
  • Fig. S4. SUVmax corresponding to tumor tissue in patients before and after CTL infusions.
  • Fig. S5. [18F]FHBG VOI delineation.
  • Fig. S6. Detailed threshold analysis to define the localization of [18F]FHBG radioactivity.
  • Fig. S7. SUVmean corresponding to tumor tissue in patients before and after CTL infusions.
  • Fig. S8. [18F]FHBG PET imaging in patient 2.
  • Fig. S9. [18F]FHBG PET imaging in patient 3.
  • Fig. S10. [18F]FHBG total activity in recurrent disease and the site of surgical resection.
  • Fig. S11. Post-CTL infusion [18F]FHBG PET and [18F]FDG PET imaging.
  • Fig. S12. [18F]FHBG PET images of a patient with a glioblastoma that originated from the dura mater.
  • Table S1. Patient survival data after diagnosis and initial CTL infusion.
  • Table S2. [18F]FHBG uptake in organs before and after CTL infusions.
  • Table S3. Injection protocol for patients 3 to 7.
  • Legend for movie S1

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Movie S1 (.mp4 format). Tumor-associated [18F]FHBG activity in the same patient before and after CTL administration.